‹ ›
MYP_140947
← PREVIOUS NEXT → BACK
Basic Information
Alloferon (4-13)
Anticancer ▸ Cytotoxic anticancer activity ▸ Cytotoxic
Antimicrobial
Antiviral
Antiviral ▸ Antiviral mechanism ▸ Viral entry inhibition
Toxicity / Safety ▸ Blood cell toxicity ▸ Hemolysis ▸ Hemolytic
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Cytotoxic
Standard
10 amino acids
C39H57N17O13
Standard
Sequence
SGHGQHGVHG
Physicochemical Analysis
971.98 Da
6.78
-0.28
-0.64
-0.0278
-1.13
0.18
0.08
-22.11
29.00
0.0000
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
474.58
-7.90
16.0
16.0
30.0
69.0
3.0
10.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0032208 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Alloferon
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Entry inhibition
inhibition of virus replication in Hep-2 cells
310 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperNew alloferon analogues: synthesis and antiviral properties. | Kuczer M, Majewska A, Zahorska R. | Chem Biol Drug Des. 2013 Feb;81(2):302-9. | DOI:10.1111/cbdd.12020 | PMID:22883213 PMID22883213 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/22883213/
RECORD: Rec_0104182 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Hemolytic
Vero cells (- at NA
Hemolysis
PMID22883213 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/22883213/
RECORD: Rec_0107834 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Alloferon
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Entry inhibition
Coxsackie virus B2 (clinical strain) | Hep-2 cells
170 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperNew alloferon analogues: synthesis and antiviral properties. | Kuczer M, Majewska A, Zahorska R. | Chem Biol Drug Des. 2013 Feb;81(2):302-9. | DOI:10.1111/cbdd.12020 | PMID:22883213 PMID22883213 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/22883213/
RECORD: Rec_0109257 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Alloferon
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Entry inhibition
HHV-1 clinical strain | Vero cells
173 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperNew alloferon analogues: synthesis and antiviral properties. | Kuczer M, Majewska A, Zahorska R. | Chem Biol Drug Des. 2013 Feb;81(2):302-9. | DOI:10.1111/cbdd.12020 | PMID:22883213 PMID22883213 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/22883213/
RECORD: Rec_0118526 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Alloferon
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Entry inhibition
Coxsackie virus 971 PT B2 | HEp-2 cells
210 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperNew alloferon analogues: synthesis and antiviral properties. | Kuczer M, Majewska A, Zahorska R. | Chem Biol Drug Des. 2013 Feb;81(2):302-9. | DOI:10.1111/cbdd.12020 | PMID:22883213 PMID22883213 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/22883213/
1 2 3 ... 5 NEXT LAST
Showing 5 records on this page · Page 1 of 5